Weiya Medical Secures Tens of Millions of Yuan in Series A Funding to Advance Leading-Edge Robotic Platform for Vascular Interventions

Wire Science, a leading domestic enterprise in minimally invasive vascular interventional surgical robots, has recently completed tens of millions of yuan in Series A financing. This round was led by Boyuan Capital, with strategic investment from Zotac Medical (02190.HK), a listed company and leader in China’s vascular intervention sector. Yicheng Capital served as the exclusive long-term financial advisor.The proceeds from this round of financing will be used for the R&D and iterative development of the company’s vascular interventional surgical robots, expansion of product indications, and acceleration of clinical progress.

Meanwhile,Wire Science Signs Strategic Cooperation Agreement with Zebra Medical. Guided by its resources in the field of vascular intervention, Zhuangchuang Tongqiao will continue to provide empowerment, jointly accelerating Wire Science’s vascular interventional surgical robot in product R&D, clinical collaboration, regulatory submission, and commercialization progress, thereby achieving synergistic development of both parties’ products and businesses and meeting broader clinical needs in vascular interventional procedures.

In the field of vascular interventional surgical robots, Wire Science is one of the few exceptional teams in China with over a decade of R&D experience.Wire Science has launched its next-generation vascular interventional surgical robot, capable of simultaneously performing angiography and interventional therapy for coronary, neurovascular, and peripheral procedures.Compared with other products in overseas markets, Wire Science’s robotic systems can simultaneously perform angiography and interventional procedures, enabling fully robot-assisted surgeries and significantly expanding clinical application scenarios.

Meanwhile, in terms of core technologies, Wire Science possesses a novel, proprietary delivery technology that has achieved breakthrough upgrades in key areas such as delivery precision, stability, and safety. This technology comprehensively meets the requirements for physicians’ interventional procedures, and its products have gained recognition from numerous top-tier experts in China. Ma Jinbo, Vice President of Investment at Boyuan Capital, stated, “Vascular interventional surgical robots offer clinical, commercial, and social value, representing a highly promising niche product worthy of sustained investment in the medical technology sector. We believe that Wire Science’s deep understanding of robotic clinical applications and its ability to iteratively develop breakthrough technologies position it to become a leading enterprise in China’s vascular interventional surgical robot field. Boyuan Capital and JVCK will leverage their respective strengths in the capital markets and industry sectors, working together with Wire Science to continuously address unmet clinical needs through groundbreaking innovative technologies, thereby revolutionizing the future of vascular interventional surgery through technological innovation.”

Following the completion of this funding round, Wire Science will continue to deepen its efforts in product upgrades, consistently enhance product application capabilities, and achieve breakthroughs in key technologies. In collaboration with its strategic shareholder, Zylox-Tonbridge, the company aims to extend the application of its surgical robots to more complex procedures, such as coronary and neuro-interventions, thereby empowering physicians to improve their interventional surgical skills. Dr. Zhao Zhong, Chairman of Zylox-Tonbridge, stated, “Wire Science is a leader in the field of vascular interventional surgical robots in China, boasting profound technological accumulation and extensive experience in medical-engineering collaborative R&D. The breakthrough technologies of Wire Science’s surgical robot products are expected to create synergies with Zylox-Tonbridge’s peripheral and neuro-interventional product portfolios, jointly driving technological innovation in vascular interventional procedures and benefiting both patients and healthcare providers. We believe that this strategic investment will help the company build a comprehensive treatment platform for vascular diseases, further enhancing Zylox-Tonbridge’s market competitiveness.”

Furthermore, Wire Science plans to integrate surgical robots with telemedicine to create an integrated platform for remote vascular intervention, contributing to the development of a telemedicine system for vascular interventions.

The founder of Wire Science stated, “For over a decade, the founding team of Wire Science has remained steadfastly committed to addressing clinical needs as its core focus, leveraging foundational technology R&D as its cornerstone, and taking the creation of disruptive products as its mission. Years of dedicated efforts have yielded significant product achievements. Wire Science will not rest on its current accomplishments but will continue to drive product iteration and technological R&D, persistently exploring technical breakthroughs for vascular interventional surgical robots in more complex procedures and diversifying their applications in telemedicine, thereby meeting the widespread demand among physicians and patients for improved outcomes in interventional surgeries.”

Boyuan Capital, established in 2017, is a specialized investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. We are not merely investors; we are long-term partners to entrepreneurs. We provide sustained support to the most exceptional healthcare founders, cultivating the next generation of leading enterprises in China’s healthcare industry.

Zhejiang ZC Medical Technology Corporation (02190.HK) is a company dedicated to the innovative R&D, manufacturing, and sales services of medical devices in the field of vascular intervention. ZC Medical has launched a series of high-end medical devices with independent intellectual property rights in the fields of peripheral and neurovascular intervention, filling gaps both domestically and internationally. We are committed to providing patients with high-quality and affordable innovative medical devices and services, enabling everyone to enjoy a high quality of life brought by advanced medical technologies.